Atopic Dermatitis: New Perspectives on Managing a Chronic Inflammatory Disease电子书

Faculty: Robert E. Kalb, MD

Jeffrey M. Weinberg, MD

Preamble: Target Audience

Educational Objectives

Statement of Need/Program Overview

References

Physician Accreditation Statement

Physician Credit Designation

Global Contact Information

Instructions to Receive Credit

Fee Information & Refund/Cancellation Policy

Disclosure of Conflicts of Interest

Disclosure of Unlabeled Use

Disclaimer

Chapter 1: Causes and Consequences of Atopic Dermatitis

Outside-In vs Inside-Out Pathoetiology in Atopic Dermatitis

Key Clinical Highlights

References

Chapter 2: Evaluating Patients With Moderate-to-Severe Atopic Dermatitis

Identifying Atopic and Nonatopic Triggers

Assessing Clinical Outcomes in Patients with Diagnosed Atopic Dermatitis

Nonatopic Comorbidities Associated with Atopic Dermatitis

Key Clinical Highlights

References

Chapter 3: Current and Emerging Therapies for Atopic Dermatitis

Traditional Systemic Therapies for Atopic Dermatitis

Newer Targeted Therapies for Moderate-to-Severe Atopic Dermatitis

Key Clinical Highlights

References

Chapter 4: Individualizing Maintenance Therapy for Moderate-to-Severe Atopic Dermatitis

Addressing Comorbid Conditions

Considering Disease Phenotypes

Monitoring Treatment Outcomes With Topical and Systemic Therapies

Key Clinical Highlights

References

Chapter 5: Educating Patients and Improving Adherence

Encouraging Shared Decision-Making

Enhancing Treatment Adherence

Key Clinical Highlights

References

Atopic Dermatitis Clinical Resource Center™: Guidelines

Patient Resources

International Eczema Council

National Eczema Association

Clinical Assessment Tools

Eczema Area and Severity Index (EASI)

Investigator Global Assessment (IGA)

Scoring Atopic Dermatitis (SCORAD)

Management of difficult-to-treat atopic dermatitis.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Translating atopic dermatitis management guidelines into practice for primary care providers.

Persistence of mild to moderate atopic dermatitis.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Serious complications from Staphylococcal aureus in atopic dermatitis.

Anti-interleukin-31 receptor A antibody for atopic dermatitis.

Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.

Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

Eczema and cardiovascular risk factors in 2 US adult population studies.

Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.

The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.

CME Posttest